Myriad Genetics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 31.2 million compared to USD 42.3 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.52 a year ago.